Table of contents


In this issue

p1 | doi:10.1038/nrd712

Editorial: Navigating the evolving world of drug discovery

p3 | doi:10.1038/nrd713

Top

Research Highlights

Toxicology: What's your poison?

p5 | doi:10.1038/nrd714

Neurodegenerative diseases: Model behaviour...

p6 | doi:10.1038/nrd700

High-throughput screening: ...And fashionable screening

p6 | doi:10.1038/nrd701

G-Protein-coupled receptors: Cheek to cheek

p7 | doi:10.1038/nrd711

Drug delivery: Insulin in disguise

p8 | doi:10.1038/nrd715

Hypolipidaemic drugs: eSCAPing high cholesterol

p8 | doi:10.1038/nrd716

DNA-binding drugs: Getting stuck in

p9 | doi:10.1038/nrd717

Drug delivery: First class delivery

p10 | doi:10.1038/nrd720

Top

News and Analysis

From the analyst's couch

Market indicators

p11 | doi:10.1038/nrd709

Top

Reviews

Strategies in the design of antiviral drugs

Erik De Clercq

p13 | doi:10.1038/nrd703

Drug discovery by dynamic combinatorial libraries

Olof Ramström & Jean-Marie Lehn

p26 | doi:10.1038/nrd704

The genetic basis of variability in drug responses

Dan M. Roden & Alfred L. George Jr

p37 | doi:10.1038/nrd705

High-throughput crystallography for lead discovery in drug design

Tom L. Blundell, Harren Jhoti & Chris Abell

p45 | doi:10.1038/nrd706

Emerging immune targets for the therapy of allergic asthma

David B. Corry

p55 | doi:10.1038/nrd702

Targeting glycosylation as a therapeutic approach

Raymond A. Dwek, Terry D. Butters, Frances M. Platt & Nicole Zitzmann

p65 | doi:10.1038/nrd708

Top

Perspectives

Timeline

Moving smaller in drug discovery and delivery

David A. LaVan, David M. Lynn & Robert Langer

p77 | doi:10.1038/nrd707

Opinion

Toxicogenomics and drug discovery: will new technologies help us produce better drugs?

Roger Ulrich & Stephen H. Friend

p84 | doi:10.1038/nrd710

Natureview: Reviews and comment from nature journals

p89 | doi:10.1038/nrd721

Extra navigation

natureproducts


Advertisement